About Contact Us Careers

Epilepsy Market Size and Forecast, by Diagnosis & Treatment (Imaging Devices, Blood Tests, Anti-Epileptic Drugs); Condition (Drug-Resistant, Intractable); Treatment (First Generation Drugs, Second Generation Drugs, Third Generation Drugs); End-user (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 4084
  • Published Date: Sep 09, 2025
  • Report Format: PDF, PPT

Epilepsy Market Outlook:

Epilepsy Market size was over USD 2.59 billion in 2025 and is poised to exceed USD 4.02 billion by 2035, growing at over 4.5% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of epilepsy is estimated at USD 2.69 billion.

Epilepsy Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The major factor attributed to the growth of the global market is the rising prevalence of epilepsy among the global population and increasing cases of neurological diseases around the globe. According to data from the World Health Organization (WHO), around 50 million people worldwide have epilepsy.

In addition to the aforementioned factors, the other factors responsible for significant revenue generation in the next few years are the surge of non-communicable diseases along with central nervous system disorders. Apart from it, the escalation in abnormal brain activities such as seizures, episodes of involuntary movements, and sensations owing to prenatal or perinatal complications, congenital abnormalities, or genetic conditions are considered to impetus the growth of the market size during the forecast period. In addition, numerous initiatives taken by governments and organizations to spread awareness about epilepsy are also estimated to provide growth opportunities for the expansion of the global epilepsy market in the coming years. Furthermore, the increasing geriatric population coupled with the presence of a strong healthcare base and rising healthcare expenditure are also attributed to creating a positive outlook for market growth during the forecast period. Moreover, the growing awareness amongst people regarding the treatment of neurological diseases, combined the with high adoption of antiepileptic drugs (AEDs) is also estimated to drive market growth.

Key Epilepsy Market Insights Summary:

  • Regional Highlights:

    • North America epilepsy market will hold around 39.5% share by 2035, driven by the increasing prevalence of epilepsy, with over 1.2% of the US population affected, supported by a strong healthcare network.
    • Asia Pacific market will register significant growth from 2026 to 2035, attributed to rising cases of neurological diseases, a growing geriatric population, and rapid healthcare industry expansion in the region.

  • Segment Insights:

    • The imaging devices (diagnosis & treatment) segment in the epilepsy market is anticipated to capture the largest share by 2035, driven by the global rise in diagnostic imaging services and investments in medical device development.
    • The hospitals segment in the epilepsy market is poised for significant growth during 2026-2035, driven by access to specialized doctors and advanced equipment, making hospitals preferred for epilepsy care.

  • Key Growth Trends:

    • Growing Prevalence of Neurological Disorders
    • Rising Cases of Brain Injuries

  • Major Challenges:

    • Rise in the Cost of the Treatment
    • Lack of Patent Protections

  • Key Players: Stryker B.V., Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., Sunovion Pharmaceuticals, Inc., Sanofi aventis Group, Koninklijke Philips N.V., Eisai Co. Ltd., Cephalon, Inc., Abbott Laboratories.

Global Epilepsy Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 2.59 billion
    • 2026 Market Size: USD 2.69 billion
    • Projected Market Size: USD 4.02 billion by 2035
    • Growth Forecasts: 4.5% CAGR (2026-2035)

  • Key Regional Dynamics:

    • Largest Region: North America (39.5% Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: United States, China, Japan, Germany, United Kingdom
    • Emerging Countries: China, India, Japan, South Korea, Brazil

    • Last updated on : 9 September, 2025

Growth Drivers

  • Growing Prevalence of Neurological Disorders – In the recent period, the growth of neurological disorders has considerably grown up as a result of several factors such as genetic disorders, lifestyle illnesses, and accidents. Thus, for the effective treatment of these neurological disorders, the demand for epilepsy is attributed to growth in the next few years. As per recent statistics, it has been stated that more than 1 billion people around the world are being affected by some kind of neurological disease. Furthermore, nearly 7 million people worldwide die every year owing to a neurological disorder.

  • Rising Cases of Brain Injuries – Brain injuries result in partial or generalized seizures, sometimes along with loss of consciousness and control of bowel or bladder function. Hence, with the growth of brain injuries among the global population, it is anticipated to fuel the revenue generation of the global epilepsy market during the assessment period. The data released by the Centers for Disease Control and Prevention (CDC), in the United States region, approximately 5.3 million men, women, and children are diagnosed with a permanent Traumatic Brain Injury (TBI) and its related disability at present time.

  • Burgeoning Geriatric Population Across the Globe – Elderly people are more prone to brain injuries owing to their weak brain and deteriorating other body organs. Hence, the rising percentage of the geriatric population is forecasted to bring profitable opportunities for the expansion of the global epilepsy market. The statistics provided by the World Health Organization (WHO) have stated that by 2030, 1 out of 6 people in the world is forecasted to fall under 60 years and above. Also, the population share of geriatrics was 1 billion in 2020 which increased to 1.4 billion in 2022 and is anticipated to grow to reach 2.1 billion by 2050.

  • Rapid Expansion of the Healthcare Industry – Recent data calculated the revenue generation of the global healthcare segment to be around USD 60 billion by the end of 2023. This sector is further projected to grow till 2027 with an annual growth of 10%.

  • The Surge in Brain Tumors in Global Population – It was calculated that in the United States region, almost 25,000 Americans out of which around 14,000 were men and 11,000 were women were diagnosed with either brain or spinal cord tumors in 2022.

Challenges

  • Rise in the Cost of the Treatment – The prevalence of epilepsy and other neurological disorders is high but their treatment cost is also very high. Thus, the population with low and middle income is not able to opt for epilepsy treatment. This factor is anticipated to hamper the market growth. 

  • Lack of Patent Protections

  • Increased Costs of Medications

Epilepsy Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Period

2026-2035

CAGR

4.5%

Base Year Market Size (2025)

USD 2.59 billion

Forecast Year Market Size (2035)

USD 4.02 billion

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Epilepsy Market Segmentation:

Diagnosis & Treatment Segment Analysis

The imaging devices segment is attributed to holding the largest share of the market during the forecast period. The major factor attributed to segment growth is the increasing diagnostic imaging services across the globe and high investments made in the medical devices sector. As of 2022, the total worth of diagnostic imaging devices was estimated to be approximately USD 45 billion globally. Furthermore, the increasing advantages of imaging devices to detect and diagnose epilepsy are also estimated to bring lucrative growth opportunities for segment growth.

End-user Segment Analysis

The hospitals segment in epilepsy market is projected to hold a significant share during the analysis period with a notable revenue generation. Effective treatment of neurological disorders and other chronic diseases is often conducted in hospitals with the availability of specialized doctors and advanced medical equipment. In addition, it’s easier and more convenient for the diagnosis and treatment processes of epilepsy and the increased inflow and outflow of patients in the hospitals for the expansion of the segment size.

Our in-depth analysis of the global market includes the following segments:

          By Diagnosis & Treatment
  • Imaging Devices
  • Blood Tests
  • Anti-Epileptic Drugs
  • Others

          By Condition
  • Epilepsy Drug-Resistant or Intractable Epilepsy
  • Others

        By Treatment
  • First Generation Drugs
  • Second Generation Drugs
  • Third Generation Drugs

        By End-User
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Diagnostic Centers
  • Others
 
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Epilepsy Market Regional Analysis:

North American Market Insights

North America region is poised to dominate around 39.5% market share by 2035. The growth of the market can be attributed to the increasing prevalence and estimated over 1.2% of the total US population had active epilepsy. Further, the presence of a strong healthcare network along with the availability of supportive policies by the regulatory bodies that promote the market players to opt for easy testing of epilepsy drugs over a large target population. In addition, the region's expanding healthcare industry and rising healthcare expenditure are also anticipated to boost market growth.

APAC Market Insights

The Asia Pacific epilepsy market is also projected to grow at a significant pace with a notable CAGR rate. The growth of the market in the region can be attributed to similar factors, such as rising cases of neurological diseases and a growing geriatric population with various types of brain disorders. Also, the rapid growth of the healthcare industry and rising investment in enhancing the healthcare system are other factors that are anticipated to create a positive outlook for generating significant revenue. Moreover, the presence of a large pool of patients and the rapid escalation of non-communicable diseases are also expected to create a positive outlook .

Epilepsy Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Epilepsy Market Players:

      • Stryker B.V.
        • Company Overview
        • Business Strategy
        • Key Product Offerings
        • Financial Performance
        • Key Performance Indicators
        • Risk Analysis
        • Recent Development
        • Regional Presence
        • SWOT Analysis
      • Johnson & Johnson Services, Inc.
      • Novartis AG
      • Pfizer, Inc.
      • Sunovion Pharmaceuticals, Inc.
      • Sanofi aventis Group
      • Koninklijke Philips N.V.
      • Eisai Co. Ltd.
      • Cephalon, Inc.
      • Abbott Laboratories

Recent Developments

  • Yuyu Pharma along with Novartis Korea joined hands for an agreement in which Yuyu acquired the exclusive distribution rights for 3 prescription medicines, including Tegretol, a medicine containing carbamazepine used to treat conditions including epilepsy.

  •  Koninklijke Philips N.V. announced the acquisition of BioTelemetry, Inc., a leading provider of remote diagnostics and monitoring.

  • Stryker B.V., a leading medical technology company, has finally acquired Wright Medical Group N.V.

     

  • Report ID: 4084
  • Published Date: Sep 09, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of epilepsy is estimated at USD 2.69 billion.

The global epilepsy market size was more than USD 2.59 billion in 2025 and is anticipated to grow at a CAGR of over 4.5%, reaching USD 4.02 billion revenue by 2035.

North America epilepsy market will hold around 39.5% share by 2035, driven by the increasing prevalence of epilepsy, with over 1.2% of the US population affected, supported by a strong healthcare network.

Key players in the market include Stryker B.V., Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., Sunovion Pharmaceuticals, Inc., Sanofi aventis Group, Koninklijke Philips N.V., Eisai Co. Ltd., Cephalon, Inc., Abbott Laboratories.

Epilepsy Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos